In the expanding frontier of ageing research, epigenetics has emerged as a beacon illuminating the intricate molecular choreography underlying cellular decline. Despite extensive documentation of age-associated epigenetic alterations, a comprehensive, integrative model elucidating their mechanistic interplay has remained elusive—until now. A groundbreaking review by Yücel and Gladyshev proposes a systems-level framework that intricately maps how epigenetic regulation governs the ageing process, transforming our understanding of cellular senescence and opening the door for innovative therapeutic strategies.
At the core of this revolutionary framework lies the concept of epigenetic fidelity — the robustness of chromatin regulatory systems to preserve precise gene expression landscapes. Epigenetic fidelity, as Yücel and Gladyshev articulate, deteriorates progressively through four intricately linked processes that collectively destabilize the cellular identity and function. These include the decay of nuclear architecture, the perturbation of epigenetic memory through chromatin modifiers, alterations in nucleosome configuration via histone variant dynamics, and transcriptional reprogramming steered by transcription factors. This multi-layered degradation ignites a cascade of failures throughout gene regulation networks, thereby advancing cellular and tissue ageing phenotypes.
The first pillar underscoring epigenetic deterioration involves the structural deconstruction of nuclear architecture, particularly the disintegration of lamina-associated domains (LADs). LADs serve as essential genomic regions tethered to the nuclear lamina, orchestrating spatial genome organization and gene repression. Disruptions to LADs compromise chromatin compaction and reposition genomic loci abnormally, leading to aberrant gene expression patterns. The authors emphasize this architectural collapse as a lynchpin that primes the chromatin landscape for widespread dysregulation during ageing.
Equally critical is the dysregulation of epigenetic memory, explicitly mediated by chromatin-modifying complexes such as the Polycomb repressive complex 2 (PRC2). PRC2’s role in maintaining repressive histone methylation marks is vital for safeguarding lineage-specific gene silencing. As ageing progresses, Yücel and Gladyshev reveal that impaired PRC2 function leads to erosion of these repressive marks, resulting in de-repression of genes that were once tightly controlled. This loss of epigenetic memory destabilizes cellular identity, fostering phenotypic drift and dysfunctional gene expression profiles that accelerate ageing.
Nucleosome alterations, specifically the replication-independent accumulation of the histone variant H3.3, constitute the third mechanism implicated in epigenetic fidelity loss. Unlike canonical histones, H3.3 is incorporated into chromatin outside of DNA replication, facilitating genome-wide chromatin dynamics. However, the progressive build-up of H3.3 during ageing disrupts nucleosome stability and chromatin compaction. This disturbance alters accessibility to regulatory elements and further compounds the misregulation of gene expression. The review elucidates how this histone variant imbalance plays a pivotal role in chromatin remodeling during the ageing trajectory.
The fourth dimension of epigenetic malfunction involves transcription reprogramming initiated by transcription factors. Ageing cells experience shifts in transcription factor activity that redirect gene expression programs away from homeostatic maintenance and towards maladaptive states. This reprogramming acts both as a consequence and a driver of epigenetic ambiguity, creating feedback loops that entrench aberrant cellular phenotypes. Yücel and Gladyshev highlight the role of these factors as both effectors and amplifiers of epigenetic dysregulation in senescent cells.
Critically, these four processes do not operate in isolation but intertwine through complex cross-regulatory feedback mechanisms. The resultant network of failures magnifies gene expression perturbations and erodes the maintenance of stable cell states, thereby propagating ageing phenotypes in a self-reinforcing manner. This interconnected landscape explains why interventions targeting epigenetic machinery exert broad-spectrum effects across diverse ageing models, irrespective of species or tissue type.
The implications of this integrated framework extend beyond descriptive biology to practical therapeutics. The authors argue compellingly that targeting epigenetic systems holistically, rather than focusing on isolated molecular lesions, promises more consistent and efficacious rejuvenation strategies. By restoring chromatin regulatory coherence, therapies can potentially reverse or attenuate cascading epigenetic failures that underpin ageing, shifting the paradigm from symptomatic treatment to root-cause modulation.
Yücel and Gladyshev’s model also sheds light on the resilience and vulnerability of chromatin-based mechanisms. It accounts for why certain epigenetic modifications commonly observed during ageing represent adaptive responses that ultimately tip into pathological regimes. Moreover, it reveals specific nodal points within chromatin regulation networks that could serve as leverage points for pharmacological intervention, making the systemic epigenetic network itself a direct therapeutic target.
From a molecular perspective, the work elegantly integrates chromatin architecture, histone modification landscapes, nucleosome dynamics, and transcriptional regulation into a cohesive system. This holistic view enables a more accurate prediction of how cellular identity is preserved or lost with time, highlighting the centrality of epigenetic integrity. Importantly, it also underscores the dynamic and plastic nature of ageing epigenomes, providing optimism that restoration of youthful epigenetic patterns is biologically plausible.
In the broader context of biomedical research, this systems-level approach aligns with emerging trends emphasizing network biology and multi-omic data integration. By transcending reductionist analyses, it embraces the complexity of ageing processes and supports the rational design of combinatorial therapies. Such interventions could simultaneously bolster nuclear architecture, enhance chromatin modifier function, regulate histone variant distribution, and recalibrate transcription factor activity to restore systemic epigenetic fidelity.
This comprehensive review thus marks a significant milestone, not only deepening mechanistic understanding but also charting a clear translational pathway. It inspires a shift in ageing research from cataloging epigenetic changes toward engineering their correction. Future studies building on this framework may unravel the precise molecular circuits that precipitate epigenetic collapse and validate targeted treatments that rejuvenate cellular epigenomes in vivo.
Ultimately, the insights presented by Yücel and Gladyshev spotlight the epigenome as a dynamic yet vulnerable system whose integrity determines cellular longevity. Through meticulous dissection of the interdependent failures compromising epigenetic fidelity, they provide a blueprint for the next generation of anti-ageing therapeutics. This strategic pivot from symptom management to systemic restoration envisions a future where age-related decline is not inevitable but treatable through precise modulation of the chromatin landscape.
The potential of such therapies extends beyond lifespan extension to enhancing healthspan, reducing frailty, and mitigating age-associated diseases. As the scientific community continues to unravel complex epigenetic networks, the principles articulated in this review offer a foundational framework poised to transform clinical approaches to ageing and longevity.
By emphasizing the modular yet interconnected nature of epigenetic dysregulation, this work positions chromatin regulatory systems at the forefront of ageing biology. It invites a new wave of innovative research bridging molecular biology, epigenomics, and therapeutics, promising to unlock the epigenetic code of ageing that governs cellular destiny across the lifespan.
Subject of Research:
Epigenetic regulation and its systemic dysregulation as a mechanistic driver of ageing and a target for therapeutic intervention.
Article Title:
Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target.
Article References:
Yücel, A.D., Gladyshev, V.N. Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target. Nat Rev Mol Cell Biol (2026). https://doi.org/10.1038/s41580-026-00958-0
Image Credits: AI Generated
DOI:
https://doi.org/10.1038/s41580-026-00958-0
Keywords:
Epigenetic fidelity, ageing, chromatin regulation, nuclear architecture, lamina-associated domains, Polycomb repressive complex 2, PRC2, histone variant H3.3, nucleosome dynamics, transcription reprogramming, chromatin-modifying complexes, gene expression, cell-state maintenance, therapeutic targets, anti-ageing therapies
